Oculis (NASDAQ:OCS) Sets New 12-Month High – Time to Buy?

Oculis Holding AG (NASDAQ:OCS)’s share price reached a new 52-week high during mid-day trading on Friday . The stock traded as high as $29.41 and last traded at $29.28, with a volume of 118532 shares. The stock had previously closed at $28.47.

Wall Street Analyst Weigh In

OCS has been the topic of several analyst reports. Lifesci Capital began coverage on shares of Oculis in a report on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 price target on the stock. Bank of America dropped their target price on Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. HC Wainwright upped their target price on Oculis from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Stifel Nicolaus raised their price target on Oculis from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Finally, JPMorgan Chase & Co. assumed coverage on Oculis in a report on Friday, December 19th. They set an “overweight” rating and a $38.00 price objective for the company. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.50.

Oculis Trading Up 2.5%

The stock’s 50-day moving average price is $24.50 and its 200 day moving average price is $20.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.47 and a quick ratio of 4.47. The firm has a market capitalization of $1.53 billion, a PE ratio of -11.58 and a beta of 0.28.

Institutional Investors Weigh In On Oculis

Several hedge funds have recently made changes to their positions in OCS. China Universal Asset Management Co. Ltd. grew its position in shares of Oculis by 100.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after buying an additional 1,000 shares in the last quarter. Aventura Private Wealth LLC bought a new stake in shares of Oculis in the fourth quarter valued at about $80,000. Millennium Management LLC purchased a new stake in Oculis in the fourth quarter worth about $312,000. Bosun Asset Management LLC bought a new position in Oculis during the 2nd quarter worth about $378,000. Finally, Marshall Wace LLP bought a new position in Oculis during the 2nd quarter worth about $393,000. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.